Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions.
Journal Information
Full Title: AAPS J
Abbreviation: AAPS J
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Conflict of InterestARK, TZS, DB, SM, MVT, PAG, AK, AM, SF, FCM, MCP, JH have patent applications pending on pharmaceutical composition comprising chloroquine or hydroxychloroquine and uses thereof. All authors are employees of Philip Morris International. Conflict of Interest ARK, TZS, DB, SM, MVT, PAG, AK, AM, SF, FCM, MCP, JH have patent applications pending on pharmaceutical composition comprising chloroquine or hydroxychloroquine and uses thereof. All authors are employees of Philip Morris International."
Funding Disclosure
Evidence found in paper:
"Funding Philip Morris International is the sponsor of this research."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025